Tectonic Therapeutic Inc. traded at $34.00 this Monday March 9th, decreasing $1.87 or 5.21 percent since the previous trading session. Looking back, over the last four weeks, Tectonic Therapeutic lost 61.52 percent. Over the last 12 months, its price rose by 59.55 percent. Looking ahead, we forecast Tectonic Therapeutic Inc. to be priced at 34.79 by the end of this quarter and at 31.73 in one year, according to Trading Economics global macro models projections and analysts expectations.
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).